Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Grunenberg

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancer Treatment Reviews|March 12, 2024
How to manage waldenström's macroglobulinemia in 2024Alexander Grunenberg, Christian Buske
Future Oncology (London, England)|June 12, 2019
Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemiaAlexander Grunenberg, Christian Buske
Deutsche Medizinische Wochenschrift (1946)|February 4, 2016
[New developments in Waldenström's macroglobulinemia]Alexander Grunenberg, Christian Buske
Deutsches Arzteblatt International|November 25, 2017
Monoclonal IgM Gammopathy and Waldenström's MacroglobulinemiaAlexander Grunenberg, Christian Buske
Expert Opinion on Pharmacotherapy|February 23, 2022
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literatureAlexander Grunenberg, Elisa Sala, Silke Kapp-Schwoerer, et al.
Visceral Medicine|December 11, 2025
Clinical, Diagnostical, and Epidemiological Findings at First Diagnosis of Alveolar Echinococcosis: A Single-Center Cohort StudyAnna-Lena Allgäuer, Lynn Peters, Alexander Grunenberg, et al.
Future Oncology (London, England)|April 1, 2020
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphomaAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
BMC Cancer|June 30, 2021
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trialAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
Oncotarget|November 27, 2016
VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in miceEva Gentner, Naidu M Vegi, Medhanie A Mulaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Treatment Reviews|March 12, 2024
How to manage waldenström's macroglobulinemia in 2024Alexander Grunenberg, Christian Buske
Future Oncology (London, England)|June 12, 2019
Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemiaAlexander Grunenberg, Christian Buske
Deutsche Medizinische Wochenschrift (1946)|February 4, 2016
[New developments in Waldenström's macroglobulinemia]Alexander Grunenberg, Christian Buske
Deutsches Arzteblatt International|November 25, 2017
Monoclonal IgM Gammopathy and Waldenström's MacroglobulinemiaAlexander Grunenberg, Christian Buske
Expert Opinion on Pharmacotherapy|February 23, 2022
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literatureAlexander Grunenberg, Elisa Sala, Silke Kapp-Schwoerer, et al.
Visceral Medicine|December 11, 2025
Clinical, Diagnostical, and Epidemiological Findings at First Diagnosis of Alveolar Echinococcosis: A Single-Center Cohort StudyAnna-Lena Allgäuer, Lynn Peters, Alexander Grunenberg, et al.
Future Oncology (London, England)|April 1, 2020
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphomaAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
BMC Cancer|June 30, 2021
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trialAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
Oncotarget|November 27, 2016
VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in miceEva Gentner, Naidu M Vegi, Medhanie A Mulaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.
Pageof 1